← Human Trials & Peer-Reviewed Studies
Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea
Plain-language guide to PMID 25684604 (2015): double-blind randomized controlled trial study of Liraglutide in 605 subjects.
Key Facts
- PMID
- 25684604
- Journal
- Diabetes research and clinical practice
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Ingwersen SH et al. (7 authors)
- DOI
- 10.1016/j.diabres.2015.01.001
- Registered trial
- NCT00614120
What This Study Did, in Plain Language
What Was Tested
Researchers studied Liraglutide in this randomized controlled trial publication.
An exploratory exposure-response analysis was conducted to investigate effects on glycated haemoglobin (HbA1c) and body weight.
Who Took Part
According to the abstract, 605 subjects were involved.
The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and parallel-group.
Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the subjects nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.
Groups ran in parallel: each of the subjects stayed in one arm throughout.
Data were derived from a published 16-week, randomized, double-blind, double-dummy, active-controlled, parallel-group trial of liraglutide in China, India and South Korea.
Demographic factors (body weight, age, gender, country) of importance for liraglutide clearance were evaluated.
What Was Measured
PubMed files the paper under topics including Asian People, Blood Glucose, China, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents and India.
Author keywords: Exposure-response, Liraglutide and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized, double-blind and parallel-group study of Liraglutide in 605 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (Diabetes research and clinical practice), a journal based in Ireland.
More context: the Liraglutide compound page.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.